Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management

Table 1

Examples of sustained release delivery systems studied in glaucoma-induced preclinical models.

Implant type	Materials	Drug loaded	Duration of drug release	Delivery method	Reference
Biodegradable PLGA film	PLGA 50 : 50	Ethacrynic acid (ECA)	10 days	Implanted in sclera	[32]
Biodegradable PCL + Lutrol F 127 disk	PCL + Lutrol F 127	Trusopt (Dorzolamide Hydrochloride)	6 months–1 year	Subconjunctival implantation	[33]
Microspheres	50 : 50 blend of PLGA 502H + PLA	Timolol Maleate	3-4 months	Subconjunctival injection	[34]
Liposomes	Dipalmitoylphosphatidylcholine (DPPC) lipids	Latanoprost	2-3 months	Subconjunctival injection	[35]